Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2015 · 10-Q
Revenue$1.49M$1.49M+15.4% vs Q1 2014 Net Income-$111.20K-$111.20KN/M vs Q1 2014 EPS Diluted$0.00$0.00N/M vs Q1 2014 Gross Profit$731,113+0.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$86,692−61.8% Margins · derivedGross margin49.1%−7.3 pt vs Q1 2014
Operating margin-7.5%+51.6 pt vs Q1 2014
Net margin-7.5%+51.6 pt vs Q1 2014
ended Mar 31, 2015 · filed May 14, 2015 · 44 d after period end